# Bioequivalence Study of Different Aprocitentan Tablet Formulations

> **NCT05196399** · PHASE1 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Aprocitentan (Formulation A)
- **DRUG:** Aprocitentan (Formulation B)

## Key facts

- **NCT ID:** NCT05196399
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-02
- **Primary completion:** 2022-03-27
- **Final completion:** 2022-04-07
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2022-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05196399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05196399, "Bioequivalence Study of Different Aprocitentan Tablet Formulations". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05196399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*